<DOC>
	<DOCNO>NCT02250001</DOCNO>
	<brief_summary>The primary objective study : To evaluate real-world safety , specifically incidence rate hepatic toxicity , pyrexia , resistance , DCV/ASV dual therapy Japanese patient chronically infected HCV GT-1 .</brief_summary>
	<brief_title>Asunaprevir/Daclatasvir Safety Surveillance Japanese Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Time Perspective : Other - For patient treat contract Bristol-Myers Kabushiki Kaisha ( BMKK ) treat physician initiate , patient data collect retrospectively contract sign . Data collect prospectively patient initiate DCV/ASV treatment contract initiate Patient Registry study - Yes ; 48 week ( Treatment : 24 week , Follow : 24 week )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients initiate DCV ASV treatment first time approve indication , dosage , administration include study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HCV</keyword>
</DOC>